Toward fulfilling the promise of molecular medicine in fragile X syndrome
about
The PI3K signaling pathway as a pharmacological target in Autism related disorders and Schizophrenia.Genes, circuits, and precision therapies for autism and related neurodevelopmental disordersGenetic disruption of voltage-gated calcium channels in psychiatric and neurological disordersAstrocytes conspire with neurons during progression of neurological diseaseCellular and synaptic network defects in autismLearning and behavioral deficits associated with the absence of the fragile X mental retardation protein: what a fly and mouse model can teach us.Treatment of neurodevelopmental disorders in adulthoodThe pathophysiology of fragile X (and what it teaches us about synapses)Neuroligins provide molecular links between syndromic and nonsyndromic autismCNVs: harbingers of a rare variant revolution in psychiatric geneticsTherapeutic approaches for shankopathiesThe unstable repeats--three evolving faces of neurological diseaseRedefining the classification of AMPA-selective ionotropic glutamate receptorsFragile X-like behaviors and abnormal cortical dendritic spines in cytoplasmic FMR1-interacting protein 2-mutant mice.Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism.Structural-functional connectivity deficits of neocortical circuits in the Fmr1 (-/y) mouse model of autism.Subcellular fractionation and localization studies reveal a direct interaction of the fragile X mental retardation protein (FMRP) with nucleolinFMRP targets distinct mRNA sequence elements to regulate protein expressionGenetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model.Neuronal connectivity as a convergent target of gene × environment interactions that confer risk for Autism Spectrum DisordersPositive feedback regulation of Akt-FMRP pathway protects neurons from cell deathUncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndromeAn evo-devo approach to thyroid hormones in cerebral and cerebellar cortical development: etiological implications for autismHigh-throughput sequencing of mGluR signaling pathway genes reveals enrichment of rare variants in autismPrioritizing the development of mouse models for childhood brain disordersProgress toward therapeutic potential for AFQ056 in Fragile X syndrome.Gestational and early postnatal hypothyroidism alters VGluT1 and VGAT bouton distribution in the neocortex and hippocampus, and behavior in rats.Arf6-GEF BRAG1 regulates JNK-mediated synaptic removal of GluA1-containing AMPA receptors: a new mechanism for nonsyndromic X-linked mental disorder.Influence of stimulant-induced hyperactivity on social approach in the BTBR mouse model of autismFragile X syndrome: mechanistic insights and therapeutic avenues regarding the role of potassium channels.mGluR5 ablation in cortical glutamatergic neurons increases novelty-induced locomotionComprehensive neurocognitive endophenotyping strategies for mouse models of genetic disordersTranslational animal models of autism and neurodevelopmental disorders.Event-related potential alterations in fragile X syndrome.Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity.Long-term memory deficits are associated with elevated synaptic ERK1/2 activation and reversed by mGluR5 antagonism in an animal model of autism.Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders.Recent challenges to the psychiatric diagnostic nosology: a focus on the genetics and genomics of neurodevelopmental disorders.Dysregulation of group-I metabotropic glutamate (mGlu) receptor mediated signalling in disorders associated with Intellectual Disability and AutismSuccessful cognitive aging in rats: a role for mGluR5 glutamate receptors, homer 1 proteins and downstream signaling pathways.
P2860
Q26766054-607AE8B2-87E3-4F5C-8AB2-018A84652CAAQ26782594-7F430E14-3FF5-497F-A8F1-83CAA099A560Q26783154-48AC757B-479A-4FBB-9421-87F7D59218E4Q26852070-F56F823D-449E-4687-8E60-DC3314E07AABQ26864843-74A7086D-C1BE-4491-A7E9-5FDF9CEF5104Q26866506-89649B45-3BA8-47B3-AF4C-2E48A1E22B4BQ27000307-0794F2F1-C779-43F8-8799-F54ECAF5E14AQ27010675-B4BA20AB-D492-4284-AE68-23045D1AB276Q27015370-3E67AD60-D178-407E-91F4-679C7D650C06Q27022289-F0EE4BA7-310B-4B9A-8061-3C921031FBEBQ27024976-F1138BC4-BE12-47B6-A1EB-7509B987A58CQ27025923-293B00F5-4B3F-4077-9BD5-5D0A4F836FD9Q27026601-5DAFA0B3-1005-4F06-AE83-B058ADAC66EEQ27301086-EDD2E59E-5006-482F-A22A-741D13D06C36Q27329063-CCE57C93-3EE6-43AA-9E35-967A4C361215Q27336359-E3E0E7C0-7E70-4FF9-97E8-635EE20CA398Q28114773-8167E20B-5228-4C93-AC0A-4CE7ED327C6FQ28117931-64640DFC-A8AF-4B9C-9248-6840367D43E6Q28261563-A301CAEE-05EE-4764-8619-029862957D57Q28396205-A831865F-76C3-404B-8AD0-2BB24F771202Q28567897-9E5BC142-CDFE-49A8-9F6E-5EA3425CE3C2Q28585288-26392FBA-55B8-4EE5-BB38-CE35FCCCDE0AQ28655923-9EAA17D2-4F9F-4735-AA08-70050707EEDAQ28730279-BC3CD9C7-B603-4546-9FA6-D45D922D0F4BQ30366940-36715B1E-FB00-4400-A7CC-B7720367B9B2Q30383696-AEF2E882-2AAF-4BF9-BF16-D4850D9B502FQ30417259-A350E6CD-E851-48B5-953D-4CC9CCC8982EQ30422340-684F2E52-CB00-4D10-A029-076DCDC18442Q30439243-C3B005BF-EFD0-4FE0-8E5D-027BC9ACC191Q30448604-0A7E07D9-8AF0-4FD9-9822-DF697B861958Q30450936-02C65DF8-3CE6-4341-B3A2-4CFD9C089DDAQ30458768-E2E5E592-6E5D-4F4C-9AED-E6107AE53AAEQ30459992-6A9186B4-078B-485F-8ED5-CE2524825F58Q30463379-0BDDADE4-B33F-4093-ADC3-ACDE4D37B916Q30535764-2C91AFD2-47E3-4353-9A5F-69A7646E988CQ33620574-9A2AA131-1EC0-4DF3-A9A0-569469E38485Q33635517-4D941D43-413A-4B75-B518-604482548995Q33718117-6B7DF737-440F-41D0-8C4B-71EC3C9AB6B6Q33877423-101812B9-0F8B-4A2D-9B39-84DCE00BF4CFQ34124967-70B2D04B-DCFB-4400-BA39-FC6B63D16C6E
P2860
Toward fulfilling the promise of molecular medicine in fragile X syndrome
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Toward fulfilling the promise of molecular medicine in fragile X syndrome
@ast
Toward fulfilling the promise of molecular medicine in fragile X syndrome
@en
Toward fulfilling the promise of molecular medicine in fragile X syndrome
@nl
type
label
Toward fulfilling the promise of molecular medicine in fragile X syndrome
@ast
Toward fulfilling the promise of molecular medicine in fragile X syndrome
@en
Toward fulfilling the promise of molecular medicine in fragile X syndrome
@nl
prefLabel
Toward fulfilling the promise of molecular medicine in fragile X syndrome
@ast
Toward fulfilling the promise of molecular medicine in fragile X syndrome
@en
Toward fulfilling the promise of molecular medicine in fragile X syndrome
@nl
P2860
P1476
Toward fulfilling the promise of molecular medicine in fragile X syndrome
@en
P2093
Mark F Bear
P2860
P304
P356
10.1146/ANNUREV-MED-061109-134644
P577
2011-01-01T00:00:00Z